Treatment of Ureaplasma Infection
Pregnant Women
For pregnant women with Ureaplasma infection, treat with azithromycin 1g orally as a single dose, or erythromycin base 500mg orally four times daily for 7 days. 1
Treatment Rationale and Evidence
The treatment approach for Ureaplasma in pregnancy is based on guidelines for non-gonococcal urethritis (NGU) and chlamydial infections, as Ureaplasma urealyticum causes 20-40% of NGU cases 1. While these older CDC STD treatment guidelines don't specifically isolate Ureaplasma, they provide the framework for managing urogenital mycoplasma infections during pregnancy.
Key considerations for pregnant women:
- Doxycycline and fluoroquinolones are contraindicated in pregnancy 1
- Erythromycin estolate is specifically contraindicated due to drug-related hepatotoxicity 1
- If erythromycin cannot be tolerated, amoxicillin 500mg orally three times daily for 7-10 days may be used, though efficacy data are limited 1
Alternative Erythromycin Regimens
If high-dose erythromycin schedules cannot be tolerated 1:
- Erythromycin base 250mg orally four times daily for 14 days, OR
- Erythromycin ethylsuccinate 800mg orally four times daily for 7 days, OR
- Erythromycin ethylsuccinate 400mg orally four times daily for 14 days
Clinical Evidence Supporting Treatment
Research demonstrates that erythromycin intervention in mycoplasma-positive pregnant women significantly reduces 2:
- Ureaplasma urealyticum sero-conversion rates
- Vertical transmission rates
- Preterm labor incidence
- Postpartum fever and puerperal infection
- Neonatal pneumonia
Critical caveat: Azithromycin resistance is emerging as a significant problem. Recent data show 9.87% of pregnant women harbor azithromycin-resistant Ureaplasma, with these resistant strains also showing cross-resistance to erythromycin, roxithromycin, and clarithromycin 3. Azithromycin-resistant infections are associated with significantly increased rates of spontaneous abortion, preterm birth, PPROM, and stillbirth 3.
Follow-up Recommendations
Repeat testing after therapy is recommended because gastrointestinal side effects of erythromycin may discourage compliance, and there are limited data on treatment effectiveness 1. Culture is preferred for confirmation of cure.
Non-Pregnant Adults
For non-pregnant adults with Ureaplasma infection, treat with doxycycline 100mg orally twice daily for 7 days as first-line therapy. 1, 4, 1
First-Line Treatment
Doxycycline is the recommended first-line agent based on:
- Superior efficacy for urogenital mycoplasma infections
- Lower cost compared to azithromycin
- No higher risk of adverse events 4
Alternative Regimens
Azithromycin 1g orally as a single dose is equally effective (97% vs 98% microbial cure rates) and should be used when 4:
- Compliance with multi-day dosing is questionable
- Patient has erratic healthcare-seeking behavior
- Unpredictable follow-up is anticipated
- Direct observed therapy is needed
Other alternatives if first-line options fail or are contraindicated 4:
- Erythromycin base 500mg orally four times daily for 7 days
- Erythromycin ethylsuccinate 800mg orally four times daily for 7 days
- Ofloxacin 300mg orally twice daily for 7 days
- Levofloxacin 500mg orally once daily for 7 days
Management of Treatment Failures
For persistent or recurrent urethritis after initial treatment 1:
First, assess compliance and partner treatment:
- Re-treat with initial regimen if non-compliant or partner untreated
If compliance was adequate:
- Perform wet mount and culture for Trichomonas vaginalis
- If negative, switch to alternative regimen for 14 days (e.g., erythromycin base 500mg four times daily for 14 days)
- Extended duration treats possible tetracycline-resistant U. urealyticum 1
Important note: Effective regimens have not been identified for patients with persistent symptoms after both doxycycline and erythromycin failure 1. These patients should be reassured that while urethritis persists, it is not known to cause complications or be sexually transmitted in this context.
Antimicrobial Susceptibility Patterns
Recent data show 5:
- Doxycycline: 91% susceptibility (drug of choice for empirical treatment)
- Josamycin: 86% susceptibility
- Ofloxacin: 77% susceptibility
- Azithromycin: 71% susceptibility
Serovar 3/14 is the most frequently isolated strain, followed by serovars 1 and 6 5.
Neonates
For neonates with documented Ureaplasma infection (bacteremia, pneumonia, or meningitis), treat with erythromycin as the drug of choice for infections not involving the central nervous system. 6
Treatment Rationale
Erythromycin is recommended based on 6:
- In vitro activity against Ureaplasma
- Limited clinical experience data
- Preliminary pharmacokinetic and safety studies in neonates
Critical Clinical Context
Major challenge: Distinguishing pathogenic infection from colonization is difficult, as Ureaplasma is frequently isolated from mucosal surfaces in the absence of overt illness 6. The frequency of clinically significant infections among colonized neonates remains unknown.
Documented Neonatal Infections
Case reports have definitively demonstrated Ureaplasma can cause 6:
- Neonatal bacteremia
- Pneumonia
- Meningitis
Association with Chronic Lung Disease
The association between U. urealyticum and development of chronic lung disease of prematurity intensifies the need for effective antimicrobial treatment knowledge 6. However, treatment decisions must weigh the risks of antibiotic exposure against uncertain benefits in colonized but asymptomatic infants.
Perinatal Exposure and Outcomes
Intrauterine detection of Ureaplasma (not just vaginal colonization) is associated with 7:
- Severe intraventricular hemorrhage
- Retinopathy of prematurity
- Bronchopulmonary dysplasia
- Unfavorable psychomotor outcomes
Ascending infection occurs in approximately 28.6% of pregnancies with vaginal Ureaplasma colonization, with particularly high rates (52.3%) in deliveries <28 weeks with PPROM or preterm labor 7.
Treatment Considerations for Specific Scenarios
For invasive infections (meningitis, bacteremia, pneumonia), treatment is particularly challenging in the neonatal period due to 8:
- Potential drug toxicity concerns
- Clinical unfamiliarity with various Ureaplasma-associated conditions
- Need to distinguish colonization from true infection
The burden of Ureaplasma exposure is inversely related to gestational age, leaving the most premature infants at highest risk 9.
Current Gaps
Recommendations for screening practices and therapeutic management in preterm infants are currently missing from major guidelines 9. Better knowledge of pathogen and host factors is needed to define screening and treatment recommendations for early intervention in at-risk preterm infants.